Human Pancreas Analysis Program for Type-2 Diabetes (HPAP-T2D) (U01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to expand the operational scope of the existing Human Pancreas Analysis Program (HPAP) to the study of pancreata recovered from tissue donors with Type 2 Diabetes (T2D) and related metabolic disorders. This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, with a program goal of further advancing research through a shared resource, by tasking the team with : 1) identifying, collecting and intensively characterizing primary pancreatic tissues from patients with T2D and related forms of islet dysfunction, as well as age-matched controls; and 2) analyzing, organizing and sharing the data resulting from the study of these tissues through use and expansion of the existing PANC DB open-access resource database. HPAP is a component of the Human Islet Research Network (HIRN), created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in Type 1 Diabetes (T1D), and to find innovative strategies to protect and replace functional human beta cell mass.

Renewal of the current activity of HPAP with its focus on T1D pathogenesis is supported through a Companion Funding Opportunity (RFA-DK-18-015).

Deadlines:

  • Letter of Intent Due Date(s): January 26, 2019
  • Application Due Date(s): February 26, 2019

​RFA-DK-18-016 Expiration Date February 27, 2019

Agency Website

Amount

$10,000,000

Amount Description

Application budgets are limited to $2 million direct costs per year.
 
The maximum project period is 5 years.

Funding Type

Grant

Eligibility

Faculty

Category

Medical
Medical - Basic Science
Medical - Translational

External Deadline

February 26, 2019